SCHEMBL7704970

SCHEMBL7704970

CC1Oc2ccc(CCN(Cc3cccc(Cl)c3)C(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 4/20 0.34
NOS1 P29475 4/20 0.34
NOS2 P35228 4/20 0.34
AOC3 Q16853 1/20 0.34
RIPK1 Q13546 1/20 0.34
SLC2A1 P11166 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34
HDAC1 Q13547 2/20 0.34
KDM4E B2RXH2 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
TAAR1 Q96RJ0 2/20 0.33
GHSR Q92847 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6310829 0.93 RIPK1 (0.36) NOS3NOS1NOS2AOC3RIPK1
SCHEMBL6302989 0.85 HDAC3 (0.35) HDAC1HDAC3HDAC2NCOR2
SCHEMBL6305576 0.85 SLC6A2 (0.33) HDAC1KDM4EHTR2ASMN1; SMN2HDAC3
SCHEMBL6302740 0.85 HDAC3 (0.43) HDAC1HTR2CSMN1; SMN2HDAC3HDAC2
SCHEMBL6608622 0.82 GAA (0.32) HDAC1HTR2CHDAC3HDAC2NCOR2
SCHEMBL5189245 0.82 SSTR4 (0.32) HDAC1HDAC3HDAC2NCOR2
SCHEMBL5188660 0.82 SSTR4 (0.32) HDAC1HDAC3HDAC2NCOR2
SCHEMBL6069204 0.81 NOS3 (0.56) NOS3NOS1NOS2GHSR
SCHEMBL7708154 0.81 PARP1 (0.44) RIPK1SLC2A1LPAR1LPAR5HDAC1
SCHEMBL6302903 0.80 NR1D1 (0.37) SLC2A1HDAC1SMN1; SMN2HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed